Pharmacotherapy of cerebellar and vestibular disorders.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
1
12
2021
medline:
29
1
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
Major therapeutic advances have been made in patients with episodic and progressive cerebellar ataxias, downbeat nystagmus and some vestibular disorders. We provide an update review on this subject highlighting important research findings from the last two years. Recently, the use of omaveloxolone for 2 years significantly improved upright stability in Friedreich's ataxia patients. In an open-label study, N-acetyl-l-leucine administered for 6-weeks significantly improved clinical impression of change, ataxia, and quality of life in patients with Niemann-Pick disease type C1. A 12-week treatment with dalfampridine was associated with improved standing balance in a subgroup of patients with multiple sclerosis. A gluten-free diet alone improved ataxia in half of patients with antiglutamic acid decarboxylase (GAD) ataxia, suggesting that gluten sensitivity might be part of the underlying pathogenesis in anti-GAD ataxia. In a head-to-head trial, both prolonged-release 4-aminopyridine (4-AP) and acetazolamide effectively reduced the attacks up to 60% in patients with episodic ataxia type 2 (EA2), albeit 4-AP had fewer adverse effects. Small observational studies have shown that patients with episodic vestibular syndrome who cannot be diagnosed as definite or probable vestibular migraine, might still improve vestibular symptoms following preventive treatment for migraine. The use of vitamin D supplementation in benign paroxysmal positional vertigo, steroids in acute unilateral vestibulopathy, and betahistine in Ménière's disease patients remains controversial. Although the use of several therapies is being established in the treatment of cerebellar and vestibular disorders, there is an urgent need for prospective controlled therapeutic trials.
Identifiants
pubmed: 34845147
doi: 10.1097/WCO.0000000000001015
pii: 00019052-202202000-00019
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-125Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gandini J, Manto M, Bremova-Ertl T, et al. The neurological update: therapies for cerebellar ataxias in 2020. J Neurol 2020; 267:1211–1220.
Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann Neurol 2021; 89:212–225.
Hasegawa S, Kumada S, Tanuma N, et al. Long-term evaluation of low-dose betamethasone for ataxia telangiectasia. Pediatr Neurol 2019; 100:60–66.
Strupp M, Teufel J, Habs M, et al. Effects of acetyl- dl -leucine in patients with cerebellar ataxia: a case series. J Neurol 2013; 260:2556–2561.
Schniepp R, Strupp M, Wuehr M, et al. Acetyl- dl -leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum Ataxias 2016; 3:8.
Bremova-Ertl T, Claassen J, Foltan T, et al. Efficacy and safety of N -acetyl- l -leucine in Niemann-Pick disease type C. J Neurol 2021; doi:10.1007/s00415-021-10717-0. [Epub ahead of print].
doi: 10.1007/s00415-021-10717-0.
Fields T, Patterson M, Bremova-Ertl T, et al. A master protocol to investigate a novel therapy acetyl- l -leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials 2021; 22:1–15.
Kalla R, Glasauer S, Büttner U, et al. 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007; 130:2441–2451.
Claassen J, Spiegel R, Kalla R, et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus - Effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 2013; 84:1392–1399.
Schniepp R, Wuehr M, Neuhaeusser M, et al. 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol 2012; 259:2491–2493.
Kremmyda O, Zwergal A, La Fougère C, et al. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. J Neurol 2013; 260:321–323.
Prosperini L, Castelli L, De Giglio L, et al. Dalfampridine to improve balance in multiple sclerosis: substudy from a randomized placebo-controlled trial. Neurotherapeutics 2020; 17:704–709.
Zesiewicz TA, Wilmot G, Han Kuo S, et al. Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia. Neurology 2018; 90:464–471.
Jen JC, Wan J. Episodic ataxias. In Handbook of Clinical Neurology . Handb Clin Neurol; 2018:205–215.
Muth C, Teufel J, Schöls L, et al. Fampridine and acetazolamide in EA2 and related familial EA. Neurol Clin Pract 2021; 11:e438–e446.
Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77:269–275.
Na S, Kim T. Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports. Neurol Sci 2021; 42:3897–3899.
Schesny M, Joncourt F, Tarnutzer AA. Acetazolamide-responsive episodic ataxia linked to novel splice site variant in FGF14 gene. Cerebellum 2019; 18:649–653.
Mitoma H, Manto M, Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord 2021; 14:10–28.
Segal Y, Bukstein F, Raz M, et al. PD-1-inhibitor-induced PCA-2 (MAP1B) autoimmunity in a patient with renal cell carcinoma. Cerebellum 2021; doi:10.1007/s12311-021-01298-9. [Epub ahead of print].
doi: 10.1007/s12311-021-01298-9.
Hadjivassiliou M, Sarrigiannis PG, Shanmugarajah PD, et al. Clinical characteristics and management of 50 patients with anti-GAD ataxia: gluten-free diet has a major impact. Cerebellum 2020; 20:179–185.
Hadjivassiliou M, Grunewald RA, Shanmugarajah PD, et al. Treatment of primary autoimmune cerebellar ataxia with mycophenolate. Cerebellum 2020; 19:680–684.
Algahtani H, Shirah B, Attar A, Alghaythee H. Contactin-associated protein-like 2 (CASPR2) autoantibody-related pancerebellar syndrome. Acta Neurol Belg 2021; doi:10.1007/s13760-021-01658-6. [Epub ahead of print].
doi: 10.1007/s13760-021-01658-6.
Lee SH, Kim JS. Acute diagnosis and management of stroke presenting dizziness or vertigo. Neurol Clin 2015; 33:687–698.
Machner B, Choi JH, Neumann A, et al. What guides decision-making on intravenous thrombolysis in acute vestibular syndrome and suspected ischemic stroke in the posterior circulation? J Neurol 2021; 268:249–264.
Byun YJ, Levy DA, Nguyen SA, et al. Treatment of vestibular migraine: a systematic review and meta-analysis. Laryngoscope 2021; 131:186–194.
Wang F, Wang J, Cao Y, Xu Z. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. Reg Anesth Pain Med 2020; 45:323–330.
Bayer O, Adrion C, Al Tawil A, et al. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials 2019; 20:813.
Domínguez-Durán E, Doménech-Vadillo E, Bécares-Martínez C, et al. Exploring the frontiers of vestibular migraine: a case series. J Vestib Res Equilib Orientat 2021; 31:91–99.
Galcanezumab for vestibular migraine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04417361 . [Accessed 6 October 2021]
Neuhauser H, Radtke A, Von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003; 60:882–883.
Rizatriptan for episodic dizziness in vestibular migraine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02447991 . [Accessed 6 October 2021]
Scholtz AW, Steindl R, Burchardi N, et al. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, noninferiority study. Clin Drug Investig 2012; 32:387–399.
Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004; 351:354–361.
Leong KJ, Lau T, Stewart V, Canetti EFD. Systematic review and meta-analysis: effectiveness of corticosteroids in treating adults with acute vestibular neuritis. Otolaryngol Head Neck Surg 2021; 165:255–266.
Sjögren J, Magnusson M, Tjernström F, Karlberg M. Steroids for acute vestibular neuronitis – the earlier the treatment, the better the outcome? Otol Neurotol 2019; 40:372–374.
Batuecas-Caletrío A, Yañez-Gonzalez R, Sanchez-Blanco C, et al. Glucocorticoids improve acute dizziness symptoms following acute unilateral vestibulopathy. J Neurol 2015; 262:2578–2582.
Acute unilateral vestibulopathy and corticosteroid treatment. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02912182 . [Accessed 6 October 2021]
Peter IW, Van Benthem PG, Aarts MCJ, et al. Insufficient evidence for the effect of corticosteroid treatment on recovery of vestibular neuritis. Otolaryngol Head Neck Surg 2012; 147:826–831.
Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011; CD008607doi:10.1002/14651858.cd008607.pub2.
doi: 10.1002/14651858.cd008607.pub2
Goudakos JK, Markou KD, Franco-Vidal V, et al. Corticosteroids in the treatment of vestibular neuritis: a systematic review and meta-analysis. Otol Neurotol 2010; 31:183–189.
Breslin NK, Varadarajan VV, Sobel ES, Haberman RS. Autoimmune inner ear disease: a systematic review of management. Laryngoscope Investig Otolaryngol 2020; 5:1217–1226.
Gorthey SW, Pathak S, Vambutas A. The correlation of clinical corticosteroid responsiveness with expression of IL-6 in peripheral blood immune cells (PBMC) in patients with autoimmune inner ear disease (AIED). Otol Neurotol 2021; 42:1422–1428.
Rajapakse A, O’Leary C, Gundelach R, et al. Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxford Med Case Rep 2020; 2020:326–329.
Strupp M, Elger C, Goldschagg N. Treatment of vestibular paroxysmia with lacosamide. Neurol Clin Pract 2019; 9:539–541.
Bayer O, Brémová T, Strupp M, Hüfner K. A randomized double-blind, placebo-controlled, cross-over trial (Vestparoxy) of the treatment of vestibular paroxysmia with oxcarbazepine. J Neurol 2018; 265:291–298.
AlGarni MA, Mirza AA, Althobaiti AA, et al. Association of benign paroxysmal positional vertigo with vitamin D deficiency: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2018; 275:2705–2711.
Yang B, Lu Y, Xing D, et al. Association between serum vitamin D levels and benign paroxysmal positional vertigo: a systematic review and meta-analysis of observational studies. Eur Arch Otorhinolaryngol 2020; 277:169–177.
Yang Z, Li J, Zhu Z, et al. Effect of vitamin D supplementation on benign paroxysmal positional vertigo recurrence: a meta-analysis. Sci Prog 2021; 104:368504211024569.
Jeong SH, Kim JS, Kim HJ, et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: a randomized trial. Neurology 2020; 95:e1117–e1125.
Goldschagg N, Teupser D, Feil K, Strupp M. No evidence for a specific vitamin D deficit in benign paroxysmal positional vertigo. Eur J Neurol 2021; 28:3182–3186.
Van Esch B, Van Der Zaag-Loonen H, Bruintjes T, Van Benthem PP. Betahistine in Ménière's disease or syndrome: a systematic review. Audiol Neurotol 2021; 1–33. doi:10.1159/000515821. [Epub ahead of print].
doi: 10.1159/000515821.
Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016; 352:h6816.
Tighilet B, Léonard J, Watabe I, et al. Betahistine treatment in a cat model of vestibular pathology: pharmacokinetic and pharmacodynamic approaches. Front Neurol 2018; 9:431.
Lezius F, Adrion C, Mansmann U, et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series. Eur Arch Otorhinolaryngol 2011; 268:1237–1240.
Ahmadzai N, Cheng W, Kilty S, et al. Pharmacologic and surgical therapies for patients with Meniere's disease: a systematic review and network meta-analysis. PLoS One 2020; 15:e0237523.
Jiang M, Zhang Z, Zhao C. What is the efficacy of gentamicin on the incidence of vertigo attacks and hearing in patients with Meniere's disease compared with steroids? a meta-analysis. J Neurol 2020; 268:3717–3727.
Molnár A, Maihoub S, Gáborján A, et al. Intratympanic gentamycine for Ménière's disease: is there a selective vestibulotoxic effect? Eur Arch Otorhinolaryngol 2020; 277:1949–1954.
Crowson MG, Patki A, Tucci DL. A systematic review of diuretics in the medical management of Ménière's disease. Otolaryngol Head Neck Surg 2016; 154:824–834.
Fisher LM, Derebery MJ, Friedman RA. Oral steroid treatment for hearing improvement in Ménière's disease and endolymphatic hydrops. Otol Neurotol 2012; 33:1685–1691.
Viola P, Pisani D, Scarpa A, et al. The role of endogenous antisecretory factor (AF) in the treatment of Ménière's disease: a two-year follow-up study. Preliminary results. Am J Otolaryngol Head Neck Med Surg 2020; 41.
Scarpa A, Cassandro C, De Luca P, et al. Therapeutic role of intravenous glycerol for Meniere's disease. Preliminary results. Am J Otolaryngol Head Neck Med Surg 2020; 41:102498.
Bertlich M, Ihler F, Spiegel JL, et al. Intratympanal administration of lidocaine in the management of Ménière's disease. Acta Otolaryngol 2021; 141:209–215.
Assessing the efficacy of a serotonin and norepinephrine reuptake inhibitor for improving Meniere's disease outcomes. https://clinicaltrials.gov/ct2/show/NCT04218123 . doi:10.31525/ct1-nct04218123. [Accessed 6 October 2021]
Staab JP. Persistent postural-perceptual dizziness. Semin Neurol 2020; 40:130–137.
Min S, Kim JS, Park HY. Predictors of treatment response to pharmacotherapy in patients with persistent postural-perceptual dizziness. J Neurol 2021; 268:2523–2532.